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Abstract
Background: Inflammation has been implicated in a variety of diseases associated with ageing, including cancer,
cardiovascular, and neurologic diseases. We have recently established that the proteasome is a pivotal regulator of
inflammation, which modulates the induction of inflammatory mediators such as TNF-a, IL-1, IL-6, and nitric oxide
(NO) in response to a variety of stimuli. The present study was undertaken to identify non-toxic proteasome
inhibitors with the expectation that these compounds could potentially suppress the production of inflammatory
mediators in ageing humans, thereby decreasing the risk of developing ageing related diseases. We evaluated the
capacity of various proteasome inhibitors to suppress TNF-a, NO and gene suppression of TNF-a, and iNOS mRNA,
by LPS-stimulated macrophages from several sources. Further, we evaluated the mechanisms by which these
agents suppress secretion of TNF-a, and NO production. Over the course of these studies, we measured the effects
of various proteasome inhibitors on the RAW 264.7 cells, and peritoneal macrophages from four different strains of
mice (C57BL/6, BALB/c, proteasome double subunits knockout LMP7/MECL-1
-/-, and peroxisome proliferator-
activated receptor-a,
-/- (PPAR-a,
-/-) knockout mice. We also directly measured the effect of these proteasome
inhibitors on proteolytic activity of 20S rabbit muscle proteasomes.
Results: There was significant reduction of chymotrypsin-like activity of the 20S rabbit muscle proteasomes with
dexamethasone (31%), mevinolin (19%), δ-tocotrienol (28%), riboflavin (34%), and quercetin (45%; P < 0.05).
Moreover, quercetin, riboflavin, and δ-tocotrienol also inhibited chymotrypsin-like, trypsin-like and post-glutamase
activities in RAW 264.7 whole cells. These compounds also inhibited LPS-stimulated NO production and TNF-a,
secretion, blocked the degradation of P-IB protein, and decreased activation of NF-B, in RAW 264.7 cells. All
proteasome inhibitors tested also significantly inhibited NO production (30% to 60% reduction) by LPS-induced
thioglycolate-elicited peritoneal macrophages derived from all four strains of mice. All five compounds also
suppressed LPS-induced TNF-a, secretion by macrophages from C57BL/6 and BALB/c mice. TNF-a, secretion,
however, was not suppressed by any of the three proteasome inhibitors tested (δ-tocotrienol, riboflavin, and
quercetin) with LPS-induced macrophages from LMP7/MECL-1
-/- and PPAR-a,
-/- knockout mice. Results of gene
expression studies for TNF-a, and iNOS were generally consistent with results obtained for TNF-a, protein and NO
production observed with four strains of mice.
Conclusions: Results of the current study demonstrate that δ-tocotrienol, riboflavin, and quercetin inhibit NO
production by LPS-stimulated macrophages of all four strains of mice, and TNF-a, secretion only by LPS-stimulated
macrophages of C57BL/6 and BALB/c mice. The mechanism for this inhibition appears to be decreased proteolytic
degradation of P-IB protein by the inhibited proteasome, resulting in decreased translocation of activated NF-B
to the nucleus, and depressed transcription of gene expression of TNF-a, and iNOS. Further, these naturally-
occurring proteasome inhibitors tested appear to be relatively potent inhibitors of multiple proteasome subunits in
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mediators in ageing humans, thereby decreasing the risk of developing a variety of ageing related diseases.
Background
Modern industrialized societies are experiencing great
increases in many age-related diseases such as diabetes,
cardiovascular, neurodegenerative diseases, and certain
types of cancer. Although numerous factors undoubtedly
contribute to this trend, significant evidence implicates
nitric oxide (NO), and inflammation, in the pathogenesis
of several of these age-related diseases [1]. A number of
studies, using experimental animal models, have demon-
strated that senescence is accompanied by increases in
production of NO in response to a variety of microbial
products. For example, lipopolysaccharide (LPS)-induced
macrophages from 22 and 32 month old CBA/CA mice
to produce approximately 5 fold and 15 fold more NO,
respectively, than LPS-stimulated macrophages from
young (2-month-old) CBA/CA mice [2]. Through
further exploration of innate inflammatory responses we
have learned that the kinetics of NO production and
TNF-a secretion differ in LPS-stimulated murine
macrophages, that induction of these inflammatory pro-
ducts are regulated by two independent signaling path-
ways, and that cytoplasmic proteasomes are key
regulators of LPS-induced inflammatory responses in
macrophages [3-7].
We have recently reviewed the important role of
proteasomes in inflammation and other macrophage
functions, and hypothesized that inhibition of protea-
some activity can suppress inflammatory responses
that contribute to ageing [8]. Many of our earlier
experiments designed to delineate the role of protea-
somes in innate inflammatory responses utilized lacta-
cystin, a potent proteasome inhibitor [7]. Lactacystin is
a synthetic compound that contains a b-lactone moi-
ety, which is responsible for lactacystin’s capacity to
block production of a number of pro-inflammatory
cytokines by LPS-stimulated macrophages [7]. Unfortu-
nately, lactacystin is very expensive and toxic even at
micromolar levels so, although it has been quite useful
for in vitro experimentation, it is not suitable for clini-
cal use [7]. As reported recently, proteasomal activities
are tightly regulated, and naturally-occurring com-
pounds (g-tocotrienol and δ-tocotrienol) are able to
inhibit or activate these activities [9].
Consequently, we sought to identify other, non-toxic
proteasome inhibitors with anti-inflammatory properties.
Specifically, we have been evaluating a number of rela-
tively inexpensive, commercially available naturally-
occurring, synthetic, and FDA approved compounds for
their capacity to inhibit proteasome activity, and the
production of nitric oxide, certain pro-inflammatory
cytokines (TNF-a,I L - 1 b, IL-6), and the iNOS enzyme.
As part of this pursuit, we recently reported that two
important inflammatory markers associated with ageing,
TNF-a and NO, were effectively decreased in chickens
whose diets were supplemented with a variety of natu-
rally-occurring, synthetic or FDA approved compounds
such as δ-tocotrienol, quercetin, riboflavin, (-) Corey lac-
tone, amiloride, and dexamethasone [10]. As described
earlier, NO production increases during ageing process
[2], which could be due to a diminished activation of
NF-signaling [11,12]. It was suggested that above men-
tioned compounds may also block the activation of NF-
, thus resulting lowering of serum TNF-a and NO
levels in chickens [10]. The important role played by
NF-in various biological functions has been described
[13].
The objective of the present study was to determine
the possible mechanisms by which δ-tocotrienol, querce-
tin, riboflavin (vitamin B2), mevinolin, dexamethasone
(as positive controls), and a -tocopherol (vitamin E)
suppress LPS-induced inflammatory responses. Dexa-
methasone, mevinolin, δ-tocotrienol, a -tocopherol,
quercetin, and riboflavin were selected due to the pre-
sence of a lactone moiety, similar to that of lactacystin,
as shown in Figure 1. We were specifically interested in
determining the extent to which these compounds
impact proteasome activities dependent on 6 protease-
active sites (i.e. X, Y, Z, LMP7, LMP2 and MECL-1
-/-),
and signaling pathways (i.e. inhibition of NF-, cleavage
of P-I) leading to LPS-induced production of NO and
TNF-a secretion in murine macrophages. The present
studies were conducted using various types of macro-
phages, including a macrophage like murine cell line
(RAW 264.7), and thioglycolate-elicited peritoneal
macrophages from C57BL/6 (normal), BALB/c, “protea-
some double subunits knockout” (lacking LMP-7
-/-/
MECL-1
-/- subunits of the proteasomes), and peroxi-
some proliferator-activated receptor-a
-/- (PPAR-a
-/-)
deficient mice. PPAR-a
-/- deficient mice were investi-
gated because they exhibit a prolonged response to
inflammatory stimuli [14,15].
Materials and methods
Reagents
Highly purified, deep rough chemotype LPS (Re LPS)
from E. coli D31m4 was prepared as described [4]. Dul-
becco’s Modified Eagle Medium (DMEM) heat-inacti-
vated low-endotoxin fetal bovine serum (FBS), and
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MD, USA) for tissue culture studies. Thioglycollate was
purchased from Sigma, Aldrich Chemical Co. (St. Louis,
MO, USA) and RNeasy mini kit from QIAGEN Sciences
(Germantown, MD, USA). RAW 264.7 cells (ATCC TIB
71) were purchased from American Type Culture Col-
lection (Manassas, VA, USA). Mevinolin, pure a,-toco-
pherol, (-) Corey lactone, amiloride-HCL, (-) riboflavin
Figure 1 Chemical structures of various compounds used in this study.
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Chemical Co (St. Louis, MO, USA). Quercetin was pur-
chased from Alfa Aesar (Johnson Matthey Co. Lancas-
tor, UK). The 50% purified δ-tocotrienol fraction from
annatto seeds was received as a gift from American
River (Boston, MA, USA).
Purification of δ-tocotrienol from 50% purified fraction of
annatto seeds
The δ-tocotrienol was purified from 50% purified frac-
tion of annatto seeds, as described previously [16]. The
purity of δ-tocotrienol was established by high pressure
liquid chromatography (HPLC) against its standard, as
reported earlier [16].
Cell culture and maintenance
The RAW 264.7 cells or mouse thioglycolate-elicited
peritoneal macrophages were maintained in DMEM
supplemented with 10% heat inactivated FBS and 10
mg/mL gentamicin at 37°C in a humidified atmosphere
with 5% CO2, as described previously [3]. Cells were
cultured in 6-well plates as described in the Tables or
legends to the Figures.
Animals
The 6-week-old female, C57BL/6, Wild Type (WT) and
BALB/c, were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA). 6-week-old female proteasome
double subunits knockouts (LMP7/MECL-1
-/-)m i c e
were obtained from Dr. John J Monaco (Department of
Molecular Genetics, University of Cincinnati Medical
Center, Cincinnati, OH, USA) and peroxisome prolifera-
tor-activated receptor-a,
-/- (PPAR-a,
-/-)w e r eb r e da t
UMKC’s Animal Facility (Kansas City, MO, USA).
Mice used in this study received humane care in com-
pliance with the principles of laboratory animal care for-
mulated by the National Society of Health Guide for the
“Care and Use of Laboratory Animals” by the US
National Society of Health (NIH Publication No 85-23,
revised 1996).
The experimental procedures involving animals were
reviewed and approved by the “Institutional Animal
Care and Use Committee of UMKC”, Medical School,
MO. All 6-week-old female mice (n = 20) were acclima-
tized to the new environment for 14 days before begin-
ning experimentation. The mice were fed ad libitum
regular commercial mouse diet and had free access to
water throughout the experiment. A 12 h light and 12 h
dark cycle was maintained during feeding period.
Chymotrypsin-like activity of 20S rabbit muscle
proteasomes
Comparative effectiveness of different doses (5 μM-320
μM) of dexamethasone, mevinolin, a,-tocopherol, δ-
tocotrienol, riboflavin, quercetin-HCL, amiloride-HCL,
and (-) Corey lactone on the suppression of chymotryp-
sin-like activity of 20S rabbit muscle proteasomes was
evaluated. For these studies, different concentrations of
each compound were prepared in media containing
0.5% DMSO. The proteasomal activities of the 20S rab-
bit muscle proteasomes (0.4 μg/mL) were assayed with
synthetic peptide substrate in 0.02 M Tris-HCl buffer
(pH 7.2). The substrate used for the chymotrypsin-like
activity was 100 μM of succinyl-Leu-Leu-Val-Tyr-amino
methyl coumarin. Fluorescence was measured (absorp-
tion at 360 nm and emission at 460 nm) using an Flx
800 microplate fluorescence reader (Bio-Tek Instru-
ments, Winooski, VT, USA).
Effects of quercetin, riboflavin, and δ-tocotrienol
(concentrations of 5 μM-40 μM) after 60 min treatment of
different proteasomal activities (chymotrypsin-like,
trypsin-like, post-glutamase) in RAW 264.7 whole cells
The comparative inhibitory effect of quercetin, ribofla-
vin, and δ-tocotrienol on the chymotrypsin-like, trypsin-
like, and post-glutamase activities of proteasome using
RAW 264.7 whole cells were carried out essentially as
reported recently [9]. Briefly RAW 264.7 cells (10 × 10
3
cells/100 μL/well) were added in white plates (96-well,
Fisher, 0877126), followed by the addition of various
concentrations of quercetin, riboflavin, or δ-tocotrienol
(5, 10, 20, or 40 μM in 100 μL; dissolved in 0.4%
dimethyl sulfoxide (DMSO). The mixtures were incu-
b a t e da t3 7 ° Ci na ni n c u b a t o ra t5 %C O 2 for 60 min.
After incubation period, the cells in the 96-well plates
were taken out 20 min prior to the addition of Caspase-
Glo reagent (brought to room temperature before addi-
tion to the wells). Caspase-Glo reagent (100 μL) was
added to each well to a total volume of 200 μL/well (tris
buffer, pH 7.5; 0.02 M). The plate were covered with a
plate sealer and incubated at room temp for 30 min.
The relative luminescence units (RLU) of assays were
read in a Promega Plate Luminometer. The chymotryp-
sin-like, trypsin-like, or post-glutamase activities were
quantitated by measuring luminescence after stimulation
of RAW 264.7 whole cells with various concentration of
each compound in a Luminometer (Promega, Madison,
Wisconsin USA), according to the directions of
manufacturer.
TNF-a, secretion and NO production by LPS-induced RAW
264.7 cells and LPS-induced thioglycolate-elicited
peritoneal macrophages of four strains of mice
LPS-induced RAW 264.7 cells
RAW 264.7 cells (1 × 10
6 cells/500 μL/well) were
adhered for 2 h in the wells. After 2 h cells were treated
with dexamethasone, mevinolin (positive controls), a,-
tocopherol, δ-tocotrienol, riboflavin, or quercetin (100
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One hour later all wells were challenged with LPS (10
ng/well; 400 μL) or medium and incubated at 37°C in
5% CO2 for 4 h (TNF-a,) or 36 h (NO). After incuba-
tion, the supernatants were collected and stored at -20°
C.
The levels of TNF-a in supernatants were measured
by Quantikine M ELISA kit (R&D System, Minneapolis,
MN, USA) according to manufacturer’si n s t r u c t i o n s .
The lower limit of detection for TNF-a in this method
is approximately, 5.0 pg/mL [4,7].
The levels of NO were determined by measuring the
amount of nitrite, a stable metabolic product of nitric
oxide, as previously reported [17]. The assay mixture
contained medium (100 μL) plus Griess reagent (100
μL), and absorption was measured at 570 nm using a
“Microplate Reader” (MR 5000; Dynatech Labs, Inc.
USA). The amount of nitrite was determined by com-
parison of unknowns using a NaNO2 standard curve.
The NO detection limit was 0.20 nM [17].
LPS-induced thioglycolate-elicited peritoneal macrophages
The procedures described above are identical to those
utilized for peritoneal macrophages except that thiogly-
colate-elicited peritoneal macrophages were adhered to
the bottom of 100 mm tissue culture plates (1 × 10
7
cells/well in 1.0 mL media) for 4 h, the supernatants
were removed, and cells were washed extensively with
medium three times. The cells were cultured overnight
in fresh media after the final wash. After overnight incu-
bation at 37°C, the cells were treated with various pro-
teasome inhibitors and LPS as described above. Viability
of peritoneal macrophages treated with various inhibi-
tors plus LPS were also determined by trypan blue dye
exclusion or a quantitative colorimetric assay with 3-
(4,5)-dimethylthiozol-2,5-diphenyl-tetrazolium bromide
(MTT) as described previously [4,7].
Effects of various compounds on the inhibition of NF-B
in LPS-stimulated RAW 264.7 cells
RAW 264.7 cells were pretreated with dexamethasone,
mevinolin, a -tocopherol, δ-tocotrienol, riboflavin, or
quercetin for 1 h, then treated with LPS (10 ng/well;
400 μL) for 4 h. Nuclear protein was extracted and the
NF-activation was measured using “electronic mobility
shift assay” (EMSA) according to the reported procedure
[18]. Nuclear protein was extracted following the recom-
mendation of the manufacturer (QIAGEN Sciences;
Germantown, MD, USA) [19]. NF-B was measured in
nuclear extracts with the respective ELISA-based com-
mercial kits (NF-p65). Nuclear protein (5 μg), was
added to each well coated with an oligonucleotide con-
taining the consensus binding site for NF-incubated
for I h. Activated NF-was detected after 1 h with pri-
mary antibody, i.e. Anti-NF-, which specifically
recognizes an epitope (p65) accessible only when the
factor is activated and bound to its target DNA. A sec-
ondary anti-IgG horseradish peroxidase conjugate allows
detection of the activated NF-by a colorimetric reac-
tion. Absorption was read within 5 min at 450 nm with
a reference wavelength of 655 nm [19].
Degradation of P-IB, protein in LPS-stimulated RAW
264.7 cells (Western blots analyses)
RAW 264.7 cells (1 × 10
6 cells/500 μL/well) were treated
with dexamethasone, mevinolin, a,-tocopherol, δ-toco-
trienol, riboflavin, or quercetin for 1 h, then stimulated
with LPS (10 ng/well; 400 μL) for 36 h. Macrophages
were washed with phosphate-buffered saline, and cyto-
plasmic extracts were prepared using cell extraction buf-
fer (Biosource, Camarillo, California, USA) supplemented
with a protease inhibitor cocktail, containing phenyl-
methylsulfonyl fluoride and phosphatase inhibitors,
according to the manufacturer’s directions [20]. Protein
concentrations were measured with BCA protein assay
kits, and Western blots analyses were used to measure
IB-a, (Santa Cruz). Each well of the gel was loaded with
40 μg of protein and gels were electrophoresed at a con-
stant 150 V 1 × Tris glycine buffer for 50 minutes. Pro-
t e i n si ng e l sw e r et r a n s f e r r e di n t ot h e“Immobilon
Transfer Membranes” (IPVH 15150; Millipore, Bedford,
Mass, USA) using the semidry transfer cell and, after
appropriate antibody treatments, the bands were visua-
lized with an enhanced chemiluminescence detection kit
(Pierce) as described previously [7,20].
Expression of TNF-a, and iNOS genes (Southern blots
analyses)
All proteasome inhibitors (a,-tocopherol, δ-tocotrienol,
riboflavin, or quercetin) were dissolved in media con-
taining 0.2% DMSO. Thioglycolate-elicited peritoneal
macrophages were prepared from 8-week-old mice as
described previously (7,17). The macrophages (1 × 10
7)
were adhered for 2 h in the wells, with a,-tocopherol
(100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or
quercetin (40 μM) for 2 h. Then all the wells were chal-
lenged with LPS (10 ng/well; 400 μL), and incubated at
room temperature for 4 h.
After 4 h, assay mixtures were centrifuged at 2,000
rpm for 20 min. Cells were harvested, and total cellular
RNA was extracted from each pellet with RNeasy mini
kit (QIAGEN Sciences; Germantown, MD, USA) accord-
ing to the instructions of the manufacturer. The RNA of
each treatment was transcribed and resulting data was
amplified and analyzed by real-time polymerase chain
reaction (RT-PCR) to quantitate gene expression of
TNF-a, and iNOS by using 1-step RT-PCR kit (QIA-
GEN, Chatsworth, CA, USA; Southern blots analyses)
according to the manufacturer’s instructions [6,7,21].
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Viability of peritoneal macrophages treated with and
without LPS plus dexamethasone, mevinolin, a,-toco-
pherol, δ-tocotrienol, riboflavin, and quercetin-HCL was
determined by trypan blue dye exclusion or a quantita-
tive colorimetric assay with 3-(4,5)-dimethyl-thiozol-2,
5-diphenyltetrazolium bromide (MTT) as reported [4,7].
Statistical Analyses
Stat View software (version 4.01, Abacus Concepts, Ber-
keley, CA) was used for the analyses of treatment-
mediated effects as compared to control group. Treat-
ment-mediated differences were detected with a two-
w a yA N O V A ,a n dw h e nt h eFt e st indicated a signifi-
cant effect, differences between the means were analyzed
by a Fisher’s protected least significant difference test.
Data were reported as means ± SD in text and Tables.
The statistical significance level was set at 5% (P < 0.05).
Results
Effects of various compounds on the chymotrypsin
activity of 20S rabbit muscle proteasomes
The anti-inflammatory effects of δ-tocotrienol, querce-
tin, riboflavin, (-) Corey lactone, amiloride and dexa-
methasone, as determined by effects on serum levels of
TNF-a, and nitric oxide in chickens, have been reported
recently [10]. In order to determine whether these com-
pounds modulate proteasome activity, chymotrypsin-like
activity of 20S rabbit muscle proteasomes was measured
after treatment with these compounds at concentrations
ranging from 5 μM to 320 μM, and compared to activity
of vehicle treated controls. Results of this study revealed
dose dependent inhibition of chymotrypsin-like activity
of 20S rabbit muscle proteasomes between 5 μM and 40
μM for mevinolin and δ-tocotrienol, and between 5 μM
to 320 μM for dexamethasone, quercetin, and riboflavin
(Table 1). The inhibitory effects of mevinolin and δ-
tocotrienol were reversed at higher concentrations
between 80 μM and 320 μM (Table 1). (-) Corey lactone
and amiloride-HCL induced dose-dependent (5 μMt o
320 μM) increases of chymotrypsin-like activity of 20S
rabbit muscle proteasomes, whereas a,-tocopherol (vita-
min E) had no effect on at the concentrations tested
(Table 1).
The results presented in Table 1 demonstrate the
capacity of several of these compounds to inhibit 20S
chymotrypsin-like activity of rabbit muscle proteasomes
at various concentrations. For subsequent experiments,
we limited testing to a single concentration for each of
these compounds. The capacity of these compounds to
inhibit 20S chymotrypsin-like activity of rabbit muscle
proteasomes at concentrations selected for subsequent
experimentation is presented in Figure 2. Confirming
our earlier results that dexamethasone (10 μM), mevino-
lin (20 μM), δ-tocotrienol (10 μM), riboflavin (40 μM),
and quercetin (40 μM), all significantly inhibited protea-
some activity (P < 0.05), while a,-tocopherol (100 μM)
did not have an effect [10]. The extent of proteasome
inhibition, compared to controls, obtained with dexa-
methasone, mevinolin, δ-tocotrienol, riboflavin, and
quercetin was 31%, 19%, 28%, 34%, and 45%, (P <0 . 0 5 ) ,
respectively (Figure 2).
According to recent reports, the 20S proteasomes con-
tain three distinct subunits (X, Y, and Z), with well
Table 1 Effects of various compounds on the chymotrypsin-like activity of 20S rabbit muscle proteasomes
1
Treatment Absorption
2
# Assay Mixture Dexame Mevino a,-Tocop δ-Tocotri Ribofl Querce Amilor (-) Cor Lact
1 20S Prot (20S P) 28486 28486 28486 28486 28486 28486 28486 28486
2 Tris + 20S P = A 25259 25259 25259 25259 25259 25259 25259 25259
3 A + DMSO
3 = B 27792 (100)
4 27792 (100)
4 27792 (100)
4 27792 (100)
4 27792 (100)
4 27792 (100)
4 27792 (100)
4 27792 (100)
4
4B + 5 μM 22340 (81) 24120 (87) 27389 (99) 21348 (77) 24567 (88) 21670 (78) 33072 (119) 31961 (115)
5B + 1 0 μM 19250 (69) 2439 (88) 26890 (97) 20122 (72) 22459 (81) 18768 (68) 55306 (199) 34740 (125)
6B + 2 0 μM 16789 (60) 22412 (81) 27560 (99) 15904 (57) 20670 (74) 16342 (59) 77262 (278) 38353 (138)
7B + 4 0 μM 15490 (56) 18704 (67) 27180 (98) 16458 (59) 18272 (66) 15246 (55) 115336 (415) 44745 (161)
8B + 8 0 μM 12540 (45) 19870 (71) 27141 (98) 18690 (67) 17650 (64) 12560 (45) 178147 (641) 39187 (141)
9 B + 160 μM 9635 (35) 23460 (84) 26870 (97) 21405 (77) 15890 (57) 11345 (41) 191209 (688) 51415 (185)
10 B + 320 μM 8726 (31) 23960 (86) 26560 (96) 25670 (92) 12780 (46) 9650 (35) 219557 (790) 65033 (234)
Dexame = Dexamethasone; Mevino = Mevinolin; a,-Tocop = a,-Tocopherol; δ-Tocotri = δ-Tocotrienol; Ribofl = Riboflavin; Querce = Quercetin;
Amilor = Amiloride; (-) Cor Lact = (-) Corey Lactone; 20S Prot = 20S Proteasomes.
1Chymotrypsin-like activity was carried out by using synthetic dipeptide substrate III (Suc-Leu-Leu-Val-Tyr-AMC) in Tris buffer pH 7.5, 0.02 M. 20S rabbit muscle
proteasomes was used. Time of incubation was 30 minutes.
2Fluorescence absorption was measured at excitation = 360 nm and emission = 460 nm.
3Each compound was dissolved in dimethyl sulfoxide (0.5% DMSO). Appropriate amount of each compound (highest concentration) was dissolved in 1.0 mL
DMSO = A stock solution; 50 μL of stock solution A was mixed with 950 μL of media = B solution. The remaining concentrations were prepared from B solution
(1:2 dilution) successively.
4Percentage of control values are in parentheses.
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Z( b2) display chymotrypsin-like, trypsin-like, and post-
glutamase actitivities, respectively [22]. In order to con-
firm that these naturally-occurring compounds (querce-
tin, riboflavin, and δ-tocotrienol) act as proteasome
inhibitors, we measured their effects on chymotrypsin-
like, trypsin-like and post-glutamase proteasome activ-
ities. These enzymatic activities in RAW 264.7 cells
were inhibited in a dose-dependent manner at concen-
trations between 5 μMa n d4 0μM (Table 2). Quercetin
and δ-tocotrienol caused 50% inhibition of chymotryp-
sin-like activity with 40 μM concentration compared to
control, whereas, riboflavin resulted only moderate inhi-
bition of 14% with this dose (Table 2). Quercetin was
the most potent inhibitor of trypsin-like (62%) and post-
glutamase (41%) activities compared to riboflavin and δ-
tocotrienol treatments (Table 2), thus confirming our
earlier results that these compounds modulate inhibition
as proteasome inhibitors [10].
Effects of various proteasome inhibitors on production of
TNF-a, and NO by LPS-stimulated RAW 264.7 cells
The anti-inflammatory properties of dexamethasone (10
μM), mevinolin (20 μM), δ-tocotrienol (10 μM), ribofla-
vin (40 μM), quercetin (40 μM), and a,-tocopherol (100
μM) were explored by pre-treating RAW 264.7 macro-
phage-like cells for 1 h with each of these compounds
followed by stimulation with LPS and measurement of
TNF-a, or nitrite in culture supernatants 4 h and 36 h,
respectively, after LPS stimulation. Quercetin (76%),
dexamethasone (70%), and riboflavin (68%) significantly
inhibited LPS-induced secretion of TNF-a, whereas, δ-
tocotrienol and mevinolin produced only moderate
reductions of 19% and 17%, respectively as compared to
controls (Figure 3). Our previous studies with LPS-sti-
mulated macrophages demonstrated that lactacystin,
which inhibits primarily chymotrypsin-like activity of
the proteasome, did not significantly inhibit TNF-a,
production (22). In order to suppress TNF-a, secretion
Figure 2 Effects of proteasome inhibitors on chymotrypsin-like activity of 20S rabbit muscle proteasomes:2 0 SR a b b i tm u s c l e
proteasomes were treated with various compounds with 100 μL dissolved in 0.5% DMSO of dexamethasone (10 μM); mevinolin (20 μM); a,-
tocopherol (100 μM); δ-tocotrienol (10 μM); riboflavin (40 μM); or quercetin-HCL (40 μM) for 30 min. Then, proteolytic activity was measured by
adding succinyl-Leu-Leul-Val-Tyr-amino methyl coumarin as substrate and measuring fluorescence (absorption at 360 nm and emission at 460
nm) using an Flx 800 microplate fluorescence reader. The treatments 1-7 correspond to: 1. Control (tris + 20S proteasomes + 0.5% DMSO); 2.
dexamethasone; 3. mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol; 6. riboflavin; 7. quercetin-HCL.
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Page 7 of 25by LPS- stimulated macrophages, both the chymotryp-
sin-like and trypsin-like enzymatic proteasomal activity
of the proteasome had to be inhibited (22). Thus, in the
current experiments (Figure 3), the capacity of the pro-
teasome inhibitors to inhibit TNF-a, secretion by LPS-
stimulated macrophages further supports the conclusion
that these inhibitors suppress both chymotrypsin-like
and trypsin-like activities of the proteasome.
We also tested the ability of proteasome inhibitors to
suppress TNF-a, secretion by LPS-stimulated macro-
phages under conditions in which macrophages were
treated simultaneously with proteasome inhibitors and
LPS. We found that the degree of inhibition of TNF-a,
secretion by simultaneous treatment with LPS and quer-
cetin (74%), dexamethasone (66%), riboflavin (65%), δ-
tocotrienol (16%), or mevinolin (11%) (data not pre-
sented) was comparable to the level of inhibition
attained when macrophages were pre-treated with pro-
teasome inhibitors. Consequently, further studies were
carried out only under pre-treatment condition.
When testing the ability of proteasome inhibitors to
block production of NO by LPS-stimulated RAW 264.7
cells, we found that dexamethasone (76%) and quercetin
(46%) were the most efficient inhibitors, while mevinolin
(34%), δ-tocotrienol (28%), and riboflavin (14%) blocked
t h ep r o d u c t i o no fN Oo n l ym o d e s t l y( F i g u r e4 ) .a,-
Tocopherol had no significant effect on the levels of
nitric oxide (Figure 4).
Effects of various proteasome inhibitors on the inhibition
of NF-B in LPS-stimulated RAW 264.7 cells
As described earlier, serum NO levels increase during
ageing, and one potential explanation involves dimin-
ished regulation of NF-B signaling with age [11,12].
Cytoplasmic NF-B is usually bound to its inhibitor,
IB, and maintained in an inactive state. NF-B
becomes activated when IB is phosphorylated, ubiquiti-
nated, and degraded by the proteasome. NF-Bt h e n
migrates to the nucleus and binds to promoter sites of a
variety of pro-inflammatory genes including TNF-a, and
iNOS [13]. We hypothesized that increased NO levels,
associated with ageing, may be attributable to increased
degradation of IB by ageing proteasomes, with resul-
tant NF-B activation. Consequently, we tested the abil-
ity of various proteasome inhibitors (dexamethasone,
mevinolin, δ-tocotrienol, riboflavin, and quercetin) to
inhibit activation of NF-B, specifically using EMSA
assays to detect NF-B in nuclear extracts of LPS stimu-
lated RAW-264.7 cells. Significant inhibition (P < 0.02)
of LPS-induced NF-B activation, compared to medium
controls, was achieved with δ-tocotrienol (56%), mevino-
lin (52%), quercetin (46%), dexamethasone (42%), and
riboflavin (34%), while a,-tocopherol (vitamin E) had no
effect (Figure 5). Thus, the capacity of each of these pro-
teasome inhibitors to suppress LPS-induced NF-B acti-
vation could account for their ability to inhibit TNF-a,
secretion, and NO production.
Effects of various proteasome inhibitors on levels of P-IB
in LPS-stimulated RAW 264.7 cells
As mentioned above, phosphorylation of IBi sap r e r e -
quisite to its degradation by the proteasome, with resul-
tant liberation, and activation of NF-B. If the
mechanism by which various proteasome inhibitors sup-
press activation of NF-B in LPS-stimulated RAW 264.7
cells involves a decreased capacity to degrade P-IB,
levels of P-IB would be expected to increase in LPS-sti-
mulated RAW-264.7 cells treated with proteasome inhi-
bitors, compared to vehicle treated controls. Pre-
treatment of LPS-stimulated RAW 264.7 cells with quer-
cetin, dexamethasone, mevinolin, riboflavin, and δ-
Table 2 Effect of quercetin, riboflavin, and δ-tocotrienol
(concentrations of 5 μM-40 μM) in RAW 264.7 cells on
proteasomal activities (chymotrypsin, trypsin, post-
glutamase) for a duration of 1 h
1
# Assay mixture
2 Chmotrypsin-
like
Ttypsin-like Post-
glutamase
Avg RLU value Avg RLU
value
Avg RLU
value
1 1. Media and
Cells
107,890 92,168 101,874
2 2. DMSO
Control
3
139,693 (100)
4 107,753 (100)
4 106,034 (100)
4
Quercetin-HCL
35 μM 133,414 (96) 84,039 (78) 105,301 (99)
41 0 μM 133,089 (95) 80,517 (75) 102,821 (97)
52 0 μM 116,890 (84) 69,853 (65) 99,211 (94)
64 0 μM 70,543 (50) 40,776 (38) 63,012 (59)
Riboflavin
75 μM 143,069 (102) 88,251 (82) 102,858 (96)
81 0 μM 131,181 (94) 86,255 (80) 101,169 (95)
92 0 μM 120.900 (87) 83,533 (78) 100,199 (94)
10 40 μM 120,720 (86) 80,054 (74) 97,495 (92)
δ-Tocotrienol*
11 5 μM 119,147 (85) 93,331 (87) 106,844 (101)
12 10 μM 116,001 (83) 91,939 (85) 103,108 (97)
13 20 μM 114,996 (82) 86,700 (80) 95,236 (90)
14 40 μM 77,882 (56) 86,006 (80) 88,735 (84)
1Proteasome-Glo (Promega) chymotrypsin-Like, trypsin-Like, and post-
glutamase cell-based assays were used. 10,000 cells were plated per well (in
100 μL of media) in a 96-well white plate. Cells were allowed to adhere to
plates for 2 h prior testing.
2Each assay were carried out according to Promega Protocols, and plates were
read with a Luminometer to give relative luminescence units (RLU) values.
3Media + cells + 0.4% dimethyl sulfoxide (DMSO) was used as control.
All concentrations of each compound contain 0.4% DMSO.
4Percentages of
control values are in parenthesis.
*Similar values were observed for this range of reference [9] in Lipids in Health
and Disease 2010, 9:143.
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Page 8 of 25tocotrienol resulted in significant increases of 90%, 70%,
58%, 50%, and 35% (P < 0.05), respectively, compared to
vehicle treated controls (Figure 6). Thus, the capacity of
these proteasome inhibitors to suppress degradation of
P-IB probably accounts for their ability to inhibit acti-
vation of NF-B, and secretion of TNF-a,a n dp r o d u c -
tion of NO in LPS-stimulated RAW 264.7 cells.
Effects of various proteasome inhibitors on the secretion
of TNF-a, by LPS-stimulated peritoneal macrophages
from BALB/c mice
In order to confirm the results obtained above using cell
cultures, we determined the effects of these proteasome
inhibitors on LPS-induced responses of thioglycolate-eli-
cited peritoneal macrophages from several strains of
mice. Serial dilutions (5 μM to 640 μM) of dexametha-
sone, mevinolin, a,-tocopherol, δ-tocotrienol, riboflavin,
and quercetin, were tested for their ability to inhibit
TNF-a, secretion by thioglycolate-elicited peritoneal
macrophages of 8-week-old female BALB/c mice stimu-
lated with LPS (Table 3). Comparable to results
obtained with RAW 264.7 cells, significant inhibition of
TNF-a, secretion was attained with all agents tested
except a,-tocopherol. Based on these results, all further
experiments were carried out using the following con-
centrations of these agents: dexamethasone (10 μM);
mevinolin (20 μM); δ-tocotrienol (10 μM); riboflavin (40
μM), and; quercetin (40 μM).
Effects of various proteasome inhibitors on secretion of
TNF-a, secretion and NO production by LPS-stimulated
peritoneal macrophages from C57BL/6 versus BALB/c
mice
The anti-inflammatory properties of dexamethasone (10
μM), mevinolin (20 μM), δ-tocotrienol (10 μM), ribofla-
vin (40 μM), quercetin (40 μM), and a,-tocopherol (100
μM) were further explored by pre-treating peritoneal
macrophages for 1 h with each of these compounds fol-
lowed by stimulation with LPS and measurement of
TNF-a, (4 h) or nitrite (36 h) in culture supernatants,
respectively, after LPS stimulation (Figures 7A, B and
8A, B).
Figure 3 The effect of proteasome inhibitors on TNF-a, secretion by LPS-stimulated RAW 264.7 cells. RAW 264.7 cells (1 × 10
6 cells/500
μL/well) were adhered for 2 h in the wells, after 2 h, the cells were treated with 100 μL dissolved in 0.5% DMSO of dexamethasone (10 μM),
mevinolin (20 μM), a,-tocopherol (100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 1 h. Then all wells were
challenged with LPS (10 ng/well; 400 μL) and incubated at 37°C 5% CO2 for 4 h. Supernatants were assayed for TNF-a, secretion by ELISA kit.
Data are presented as the percent of TNF-a, levels compared to controls. The kit control TNF-a, value was 287. The treatments 1-7 correspond
to: 1. Control (media + cells + LPS [10 ng/mL] + 0.5% DMSO); 2. dexamethasone; 3. mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol; 6. riboflavin; 7.
quercetin-HCL.
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Page 9 of 25All the inhibitors, except a,-tocopherol, inhibited LPS-
induced secretion of TNF-a, by macrophages from
C57BL/6 mice. Dexamethasone was the most potent
inhibitor, yielded a 68% decrease in TNF-a, secretion (P
< 0.02), whereas, quercetin (37%), riboflavin (31%), mevi-
nolin (24%), and δ-tocotrienol (20%) resulted in only
moderate, but significant decreases (P < 0.05), compared
to controls (Figure 7A). Similarly, the results with macro-
phages derived from BALB/c mice paralleled those of
macrophages from C57BL/6 mice; decreases in the levels
of TNF-a, were observed with dexamethasone (72%; P <
0.02), quercetin (28%), riboflavin (25%), mevinolin (17%),
and δ-tocotrienol (15%), compared to controls (Figure
7B). The extent to which TNF-a, secretion by LPS-sti-
mulated macrophages was blocked by these various pro-
teasome inhibitors was slightly greater for C57BL/6 mice
than for BALB/c mice (~ 20%), though these differences
were not statistically significant (Figure 7B).
Production of NO by LPS-stimulated macrophages
from C57BL/6 and BALB/c mice was significantly (P <
0.02) reduced by dexamethasone (60% and 48%, respec-
tively), δ-tocotrienol (46% and 41%, respectively), and
quercetin (51% and 36%, respectively), compared to
respective controls (Figure 8A, B). However, mevinolin
( 2 7 %a n d2 2 % )a n dr i b o f l a v i n( 2 3 %a n d2 5 % )p r o d u c e d
only moderate reductions in NO production compared
to controls (Figure 8B). As with TNF-a, the extent to
which NO production by LPS-stimulated macrophages
was blocked by these various proteasome inhibitors was
slightly greater for C57BL/6 mice than for BALB/c mice
(~ 20%), though these differences were not statistically
significant (Figure 8B). Thus, these studies clearly
demonstrate that the proteasome inhibitors tested sup-
press secretion of TNF-a, and production of NO by
LPS-stimulated thioglycolate-elicited peritoneal macro-
phages derived from C57BL/6 and BALB/c mice.
Figure 4 The effect of proteasome inhibors on NO production by LPS-stimulated RAW 264.7 cells. RAW 264.7 cells (1 × 10
6 cells/500 μL/
well) were adhered for 2 h in the wells, after 2 h, the cells were treated with 100 μL dissolved in 0.5% DMSO of dexamethasone (10 μM),
mevinolin (20 μM), a,-tocopherol (100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 1 h. Then all wells were
challenged with LPS (10 ng/well; 400 μL) and incubated at 37°C 5% CO2 for 36 h. Supernatants were assayed for the production of NO by
measuring the amount of nitrite using the Griess reagent. Data are presented as the percent of NO levels compared to controls. The treatments
1-7 correspond to: 1. Control (media + cells + LPS [10 ng/mL] + 0.5% DMSO); 2. dexamethasone; 3. mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol;
6. riboflavin; 7. quercetin-HCL.
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Page 10 of 25Comparative effects of various proteasome inhibitors on
TNF-a, secretion and NO production by LPS-stimulated
thioglycolate-elicited peritoneal macrophages from
C57BL/6, BALB/c, double knockout LMP7/MECL-1
-/-, and
PPAR-a,
-/- knockout mice
The next series of experiments were conducted with
macrophages from mice that have aberrant responses to
LPS. It has previously been well documented that
macrophages from PPAR-a
-/- mice produce an unu-
sually robust and inflammatory response to LPS [14,15].
Similarly, we have been studying the effect of role of
various proteasome subunit knockouts on the inflamma-
tory response to LPS [22,23]. Of particular relevance, we
reported that LPS-stimulated peritoneal macrophages
derived from double knockout LMP7/MECL-1
-/- mice
generated a relatively normal TNF-a, response, but a
markedly reduced NO response, compared to control
(C57BL/6) mice [22]. Consequently, we thought it
would be of value to determine the effect of proteasome
inhibitors on TNF-a, and NO production by LPS-stimu-
lated macrophages from these mouse strains. The
experiments were carried out only with three lead, natu-
rally-occurring non-toxic, commercially available com-
pounds (δ-tocotrienol, riboflavin, and quercetin), which
inhibit the secretion of TNF-a, and production of NO,
which are increased during ageing process [2]. There-
fore, the anti-inflammatory properties of δ-tocotrienol
(10 μM), riboflavin (40 μM), quercetin (40 μM), and a,-
tocopherol (100 μM; as a control)) were explored in
LPS-induced thioglycolate-elicited peritoneal macro-
phages derived from knockout LMP7/MECL-1
-/- and
PPAR-a,
-/- mice using identical conditions for this series
of experiments as described in the previous paragraph
for the measurement of TNF-a, (4 h) or nitrite (36 h) in
culture supernatants, respectively, after LPS-stimulation
with the expectation that these experiments would pro-
vide further insight into the mechanisms by which these
proteasome inhibitors suppress inflammatory responses;
Figure 5 The effect of proteasome inhibitors on translocation of NF-B to the nucleus in LPS-stimulated RAW 264.7 cells. RAW 264.7
cells (1 × 10
6 cells/500 μL/well) for 2 h, after 2 h, the cells were treated with 100 μL dissolved in 0.5% DMSO of dexamethasone (10 μM),
mevinolin (20 μM), a,-tocopherol (100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 1 h. Then all the wells were
challenged with LPS (10 ng/well; 400 μL) and incubated at 37°C 5% CO2 for 36 h. At that time nuclear protein was extracted NF-B activation
was measured using “electronic mobility shift assay” (EMSA). Data are presented as the percent of nuclear NF-B levels compared to controls.
The treatments 1-7 correspond to: 1. Control (media + cells + LPS [10 ng/mL] + 0.5% DMSO); 2. dexamethasone; 3. mevinolin; 4. a,-tocopherol;
5. δ-tocotrienol; 6. riboflavin; 7. quercetin-HCL.
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Page 11 of 25macrophages from C57BL/6 and BALB/c mice were
used as controls.
LPS-induced TNF-a, secretion and NO production by
macrophages derived from C57BL/6 and BALB/c mice
were significantly inhibited (53% to 79% for TNF-a, and
24 to 51% for NO) by δ-tocotrienol, riboflavin, and
quercetin; a,-tocopherol produced no inhibitory effect
(Figure 9A). In contrast, none of these proteasome inhi-
bitors suppressed secretion of TNF-a, in double knock-
out LMP7/MECL-1
-/- mice or PPAR-a,
-/- knockout
mice compared to controls (Figure 9B). Interestingly, δ-
tocotrienol and riboflavin actually produced significant
increases in LPS-induced TNF-a, secretion by macro-
phages from PPAR-a,
-/- knockout mice. In marked con-
trast to our findings with TNF-a, all compounds, except
a,-tocopherol significantly blocked the production of
NO (32 to 60%) by LPS-stimulated macrophages from
double knockout LMP7/MECL-1
-/- mice and PPAR-a,
-/-
knockout mice, compared to controls, (Figure 10A, B).
We previously reported that NO production by LPS-
stimulated peritoneal macrophages was markedly
reduced in LMP7/MECL-1
-/- knockout mice; TNF-a,
production, in contrast, was not markedly affected by
the LMP7/MECL-1
-/- g e n o t y p e[ 2 3 ] .W ea l s od e m o n -
strated that in order to suppress TNF-a,p r o d u c t i o nb y
LPS stimulated macrophages with proteasome inhibitors,
both chymotrypsin- and trypsin-like proteasome activ-
ities must be suppressed [22]. Thus, the capacity of δ-
tocotrienol, riboflavin, and quercetin to block TNF-a,
production in C57BL/6 and BALB/c, but not in LMP7/
MECL-1
-/-, would be explained if these agents inhibited
primarily the LMP2, LMP7 and MECL-1 subunits of
mouse immunoproteasomes, with comparatively lower
suppressive effects on X, Y, and Z subunits of constitu-
tively expressed proteasomes. LPS-stimulation of macro-
phages from C57BL/6 and BALB/c would induce
production of immunoproteasomes in which X, Y and Z
subunits were partially replaced by LMP2, LMP7 and
Figure 6 The effect of proteasome inhibitors on intracellular levels of P-IB, protein in LPS-stimulated RAW 264.7 cells (Western blots
analyses). RAW 264.7 cells (1 × 10
6 cells/500 μL/well) for 2 h, after 2 h, the cells were treated with 100 μL dissolved in 0.5% DMSO of
dexamethasone (10 μM), mevinolin (20 μM), a,-tocopherol (100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 1 h.
Then all the wells were challenged with LPS (10 ng/well; 400 μL) and incubated at 37°C 5% CO2 for 36 h. Cells were washed with phosphate
buffer saline, and cytoplasmic extracts were prepared using cell extraction buffer supplemented with phenylmethylsulfonyl fluoride and
phosphatase inhibitors, according to the directions of manufacture [20]. Protein concentrations were measured with BCA protein assay kits, and
P-IB-a, levels were measured by Western blots analyses [7,20]. Data are presented as the percent of P-IB compared to controls. The treatments
1-7 correspond to: 1. Control (media + cells + LPS [10 ng/mL] + 0.5% DMSO); 2. dexamethasone; 3. mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol;
6. riboflavin; 7. quercetin-HCL.
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-/-, decreased TNF-a, production would occur if
these latter subunits were potently suppressed by δ-
tocotrienol, riboflavin, and quercetin. In contrast, the ×
and Z components of LPS-stimulated macrophages from
LMP7/MECL-1
-/- mice, could not be replaced by LMP7
and MECL-1
-/-. If the chymotrypsin-like or trypsin-like
activities of × and Z proteasome subunits were com-
paratively resistant to the inhibitory effects of δ-tocotrie-
nol, riboflavin, and quercetin, TNF-a,p r o d u c t i o nb y
LPS-stimulated macrophages from LMP7/MECL-1
-/-
mice would be unaffected, since inhibition of both chy-
motrypsin- and trypsin-like proteasomal activities are
required to suppress TNF-a, secretion.
The capacity of δ-tocotrienol, riboflavin, and quercetin
to inhibit NO production by LPS-stimulated macro-
phages from LMP7/MECL-1
-/- mice might be explained
by the high sensitivity of NO production to modulation
of immunoproteasome subunits [22,23]. Thus, we pre-
viously demonstrated that LPS-stimulated macrophages
from LMP2
-/- knockout mice produce substantially less
NO than control littermates, and concluded from those
experiments that inducible immunoproteasome subunits
play a critical role in NO production [23]. Thus, NO
production by LPS-stimulated macrophages from
LMP7/MECL-1
-/- mice is very low, therefore IFN-g has
to be added concurrently to observe NO production and
the defect is reversed. The present inhibitors suppress
the LPS-induced NO production in the presence of
IFN-g (Figure 10A, B)
Effect of various proteasome inhibitors on gene
expression of TNF-a, and iNOS by LPS-stimulated
thioglycolate-elicited peritoneal macrophages from
C57BL/6, BALB/c, double knockout LMP7/MECL-1
-/-, and
PPAR-a,
-/- knockout mice
The experiments described above demonstrated that δ-
tocotrienol, riboflavin, and quercetin inhibited secre-
tion of TNF-a, by LPS-stimulated thioglycolate-elicited
peritoneal macrophages from C57BL/6 and BALB/c,
but not LMP7/MECL-1
-/- or PPAR-a,
-/- knockout mice
(Figures 9A, B). In contrast, these compounds all
inhibited NO production by LPS-stimulated thioglyco-
late-elicited peritoneal macrophages from all four
strains of mice (Figure 10A, B). In order to determine
whether these changes resu l t e df r o ma l t e r a t i o n si n
transcription of the relevant genes, we measured the
effect of various proteasome inhibitors on mRNA
levels for TNF-a, and iNOS in LPS-stimulated thiogly-
colate-elicited peritoneal macrophages from 8-week-
old female C57BL/6, BALB/c, double knockout LMP7/
MECL-1
-/-,a n dP P A R - a,
-/- mice. The concentrations
of each inhibitor and condition were similar to those
used in earlier experiments. Cells were treated with δ-
tocotrienol (10 μM), riboflavin (40 μM), and quercetin
(40 μM) for 1 h, then LPS (10 μLo f1 . 0μg/mL) was
added to each well and incubated for an additional 4
h. Total cellular RNA was then extracted and reverse-
transcribed, and gene analyses were carried out by RT-
PCR and Southern blots analyses.
Table 3 Effects of various compounds on the secretion of TNF-a,( pg/mL) in LPS-stimulated (pre-treatment)
thioglycolate-elicited peritoneal macrophages of 8-week-old BALB/c female mice
1
Pre-treatment Secretion of TNF-a,( pg/mL)
# Assay Mixture Dexamethasone Mevinolin a,-Tocopherol δ-Tocotrienol* Riboflavin Quercetin
1 Media + Cells = A
2 A + LPS (10 ng/mL) = B 1224 1224 1224 1224 1224 1224
3 B + 0.2% DMSO
2 = C 1305 (100)
3 1305 (100)
3 1305 (100)
3 1305 (100)
3 1305 (100)
3 1305 (100)
3
4C + 5 μM 333 (26) 1125 (86) 1280 (98) 938 (72) 1012 (76) 980 (75)
5C + 1 0 μM 283 (22) 1064 (82) 1267 (97) 962 (74) 896 (69) 873 (67)
6C + 2 0 μM 234 (18) 1012 (78) 1235 (95) 834 (64) 674 (52) 846 (65)
7C + 4 0 μM 213 (16) 1048 (80) 1259 (96) 769 (59) 621 (48) 821 (63)
8C + 8 0 μM 207 (16) 1140 (87) 1298 (99) 1673 (128) 544 (42) 778 (60)
9 C + 160 μM 133 (10) 1396 (107) 1323 (101) 1732 (133) 520 (40) 472 (36)
10 C + 320 μM 112 (9) 1443 (111) 1257 (96) 1987 (152) 480 (37) 345 (26)
11 C + 640 μM 85 (7) 1487 (114) 1241 (95) 2245 (172) 406 (31) 310 (24)
1The thioglycolate-elicited peritoneal macrophages (1.0 mL) were adhered to the bottom of 12 well plates (1 × 10
7 cells/well in 1.0 mL media) for 4 h, then cells
were washed extennsively with medium 3-times. Then cells were cultured overnight in fresh media. After overnight incubation at 37°C in an incubator at5 %
CO2 for 1 h, then cells were treated with different concentrations of various compounds for 1 h. after 1 h, LPS (10 μL of 1.0 μg/mL stock solution) was added to
each well (LPS final concentration 10.0 ng/mL). The supernatants were collected after 4 h of incubation at room temperature. The supernatants were collected
after 4 h of LPS challenge, and stored at -70°C to carry out TNF- a, ELISA assay. Cells viability were > 95% in all treatments.
2Each compound was dissolved in dimethyl sulfoxide (0.2% DMSO). Appropriate amount of each compound (highest concentration) was dissolved in 1.0 mL
DMSO = A stock solution; 50 μL of stock solution A was mixed with 950 μL of media = B working solution. The remaining concentrations were prepared from B
working solution (1:2 dilution) successively.
3Percentages of control values are in parenthesis.
*Values from reference [10] in Lipids in Health and Disease 2011,10:39.
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Page 13 of 25Figure 7 Effects of various compounds on the secretion of TNF-a, in LPS-stimulated (pre-treatment) peritoneal macrophages of 8-
week-old C57BL/6 versus BALB/c female mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-week-old C57BL/6 and
BALB/c (5 of each) female mice as described previously [6]. The macrophages of each mouse were adhered to the bottom of 12 well plates (1 ×
10
7 cells/well in 1 mL media) for 4 h, the cells were washed with media three times. The cells were cultured overnight in the fresh media (500
μL) after the final wash. The cells were treated with 100 μL dissolved in 0.2% DMSO of dexamethasone, 10 μM; mevinolin, 20 μM; δ-tocotrienol,
10 μM; a,-tocopherol, 100 μM; riboflavin, 40 μM; or quercetin-HCL, 40 μM for I h, followed by stimulation with LPS (10 ng/mL) of each treatment.
The assay mixtures were incubated at room temperature for 4 h, and the assay mixtures were centrifuged at 2,000 rpm for 20 min. The cells
were then harvested, and the total cellular RNA was extracted from each pellet with RNeasy mini kit according to manufacturer’s instructions
[7,17]. The total secretion of TNF-a, of each inhibitor was estimated in the supernatants by radio-immunoassay (ELISA) kit according to the
manufacture directions [7,17]. The cells viability were very good (> 95%) in all the treatments [4,7]. Data are means ± SD, n = 5 per treatment,
and triplicate analyses of each sample. The treatments 1-7 correspond to: 1. Control (macrophages + LPS + 0.2% DMSO); 2. dexamethasone; 3.
mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol; 6. riboflavin; 7. Quercetin-HCL. Values in a column with a different superscript symbols are
significantly different at P < 0.05, A = values, B = Percentages.
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Page 14 of 25Figure 8 Effects of various compounds on the productions of nitric oxide (NO) in LPS-stimulated (pre-treatment) peritoneal
macrophages of 8-week-old C57BL/6 versus BALB/c female mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-
week-old C57BL/6 and BALB/c (5 of each) female mice as described previously [6]. The macrophages (1 x10
7 cells/well in 1.0 mL media) were
adhered to the bottom of 100 mm tissue culture plate for 4 h. After 4 h the cells were treated with each compound (100 μL dissolved in 0.2%
DMSO) of dexamethasone, 10 μM; mevinolin, 20 μM; a,-tocopherol, 100 μM; δ-tocotrienol, 10 μM; riboflavin, 40 μM; or quercetin-HCL, 40 μM for I
h, followed by stimulation with LPS 10 ng/mL (10 μL of 1.0 μg/mL) of each treatment. The assay mixtures were incubated at room temperature
for 4 h, after 4 h, the assay mixtures were centrifuged at 2,000 rpm for 20 min. The cells were then harvested, and the total cellular RNA was
extracted from each pellet with RNeasy mini kit according to manufacturer’s instructions [17]. The total level of NO for each inhibitor was
estimated in the supernatant by using Griess reagent as described earlier [7,17]. The cells viability were very good (> 95%) in all the treatments
[4,7]. Data are means ± SD, n = 5 per treatment, and triplicate analyses of each sample. The treatments 1-7 correspond to: 1. Control
(macrophages + LPS + 0.2% DMSO); 2. dexamethasone; 3. mevinolin; 4. a,-tocopherol; 5. δ-tocotrienol; 6. riboflavin; 7. quercetin-HCL. Values in a
column with a different superscript symbols are significantly different at P < 0.05, A = values, B = Percentages.
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Page 15 of 25Figure 9 Effects of various compounds on the secretion of TNF-a, in LPS-stimulated thioglycolate-elicited peritoneal macrophages of
8-week-old C57BL/6, BALB/c, double subunits knockout (LMP-7/MECL-1
-/-), and PPAR-a,
-/- female mice. Thioglycolate-elicited peritoneal
macrophages of each mouse were adhered to the bottom of 12 well plates (1 × 10
7 cells/well in 1.0 mL media) for 4 h. After 4 h, the cells were
washed with media three times. The cells were cultured overnight in the fresh media (500 μL) at 37°C in an incubator at 5% CO2 after the final
wash. After 4 h the cells were treated with each compound (100 μL dissolved in 0.2% DMSO) of a,-tocopherol, 100 μM; δ-tocotrienol, 10 μM;
riboflavin, 40 μM; or quercetin-HCL, 40 μM for I h, and the LPS (10 μL of 1.0 μg/mL) was added to assay mixture. The assay mixtures were
incubated for 4 h at room temperature. The supernatants were collected after 4 h of LPS challenge, and stored at -70°C to carry out TNF-a,
assay by ELISA. The cells viability were very good (> 95%) in all the treatments. The treatments 1-5 correspond to: 1. Control (media +
macrophages (cells) + LPS + 0.2% DMSO); 2. a,-tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5. quercetin-HCL.
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Page 16 of 25Figure 10 Effects of various compounds on the induction of NO in LPS-stimulated thioglycolate-elicited peritoneal macrophages of 8-
week-old C57BL/6, BALB/c, double subunits knockout (LMP-7/MECL-1-/-), and PPAR-a, female mice. Thioglycolate-elicited peritoneal
macrophages of each mouse were adhered to the bottom of 12 well plates (1 × 10
7 cells/well in 1.0 mL media) for 4 h. After 4 h, the cells were
washed with media three times. The cells were cultured overnight in the fresh media (500 μL) at 37°C in an incubator at 5% CO2 after the final
wash. The cells were treated with 100 μL dissolved in 0.2% DMSO of a,-tocopherol, 100 μM; δ-tocotrienol, 10 μM; riboflavin, 40 μM; or quercetin-
HCL, 40 μM for I h, and the LPS + IFN-g (10 μL of 1.0 μg/mL + 50 units/mL) was added to assay mixture. The assay mixtures were incubated for
36 h at room temperature. The supernatants were collected after 36 h of LPS challenge, and stored at -70°C to carry out NO estimation, using
the Greiss reagent. The cells viability were very good (> 95%) in all the treatments. The treatments 1-5 correspond to: 1. Control (media +
macrophages (cells) + LPS + IFN-g + 0.2% DMSO); 2. a,-tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5. quercetin-HCL.
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Page 17 of 25Each of the above proteasome inhibitors tested, except
a,-tocopherol, significantly reduced mRNA expression
for TNF-a, and iNOS in LPS-stimulated, thioglycolate-
elicited peritoneal macrophages derived from female
C57BL/6 mice (Figure 11A, B). Gene expression for
TNF-a, and iNOS was markedly reduced by treatment
with δ-tocotrienol (75% and 85%, respectively), riboflavin
(29% and 75%, respectively), and quercetin (83% and
90%, respectively), compared to controls (Figure 11A,
B). With LPS-stimulated macrophages from BALB/c
mice, there was also significant reduction (P <0 . 0 5 )o f
gene expression for TNF-a,a n di N O Sb yδ-tocotrienol
(54% and 26%, respectively), riboflavin (22% and 29%,
respectively), and quercetin (62% and 40%, respectively),
compared to controls, though the extent of inhibition
was generally lower than that observed with C57BL/6
mice (Figure 12A, B).
In LPS-stimulated macrophages from LMP7/MECL-
1
-/- knockout mice, the pattern of inhibition of mRNA
production for TNF-a,a n di N O Sg e n e sb yp r o t e a s o m e
inhibitors varied markedly from that observed with
either C57BL/6 or BALB/c mice. None of the protea-
some inhibitors had any effect on TNF-a,m R N A
expression (Figure 13A), but inhibition of iNOS mRNA
was attained with δ-tocotrienol (44%), riboflavin, (11%)
and quercetin (51%) compared to control (Figure 13B).
In LPS-stimulated macrophages from PPAR-a,
-/-
knockout mice, the pattern of inhibition of mRNA pro-
duction for TNF-a, and iNOS genes by proteasome
inhibitors also varied markedly from that observed with
either C57BL/6 or BALB/c mice, and more closely
resembled the pattern obtained with LMP7/MECL-1
-/-
knockout mice. As with LMP7/MECL-1
-/- mice, protea-
some inhibitors did not affect TNF-a, mRNA levels
(Figure 14A). Treatment with quercetin markedly sup-
pressed iNOS mRNA levels (77%); iNOS gene expres-
sion was inhibited less profoundly by δ-tocotrienol
(20%) and riboflavin (14%) (Figure 14B). In summary,
results of mRNA expression studies were generally con-
sistent with those of TNF-a, secretion and NO produc-
tion, though the enhanced secretion of TNF-a,b yL P S -
stimulated macrophages from PPAR-a,
-/- knockout mice
treated with riboflavin and δ-tocotrienol was not
explained by a corresponding increase in mRNA levels.
Moreover, quercetin was found to be slightly better
anti-inflammatory compound for the above mentioned
markers than δ-tocotrienol and riboflavin.
Discussion
T h ep r i m a r yo b j e c t i v e si nt h ep r e s e n ts t u d yw e r et o
further evaluate several naturally-occurring proteasome
inhibitors for their capacity to suppress inflammatory
processes, and to define mechanisms responsible for
these anti-inflammatory effects. Anti-inflammatory
properties of the proteasome inhibitors were evaluated
in macrophages derived from several sources (e.g. the
RAW 264.7 cell line, and thioglycolate-elicited perito-
neal macrophages from four strains of mice (C57BL/6,
BALB/c, double knockout LMP7/MECL-1
-/- and PPAR-
a,
-/-). As a result of these studies we have identified sev-
eral naturally-occurring proteasome inhibitors that
could potentially decrease levels of inflammatory cyto-
kines and NO that may contribute to the development
of diseases associated with ageing.
First, we demonstrated that dexamethasone, mevino-
lin, δ-tocotrienol, riboflavin and quercetin are potent
inhibitors of chymotrypsin-like activity of 20S rabbit
muscle proteasomes, and that (-) Corey lactone and
amiloride enhanced this activity. We also demonstrated
that dexamethasone, mevinolin, δ-tocotrienol, riboflavin
and quercetin inhibited the secretion of TNF-a and NO
production by LPS-stimulated RAW 264.7 macrophage
like murine cell cultures. Further, levels of NF-within
the nucleus were decreased, whereas cellular P-Ilevels
were increased, by pre-treatment of LPS-stimulated
RAW 264.7 cells with dexamethasone, mevinolin, δ-
tocotrienol, riboflavin and quercetin.
NF-is maintained in an inactive state in the cyto-
plasm of cells when it is bound to I. LPS induces a ser-
ies of events that results in phosphorylation and
ubiquitination of Iwith subsequent degradation by the
proteasome. These actions result in NF-activation,
translocation to the nucleus, and increased transcription
of several genes encoding pro-inflammatory cytokines.
Consequently, the capacity of dexamethasone, mevino-
lin, δ-tocotrienol, riboflavin and quercetin to inhibit pro-
teasome activity in conjunction with their capacity to
increase cellular levels of P-Iand decrease nuclear
translocation of NF-, suggests that the mechanism by
which these agents suppress production of TNF-a,a n d
NO involves decreased degradation of ubiquinated P-
Iby the proteasome, resulting in depressed transloca-
tion of NF-to the nucleus. Therefore, ultimately, these
proteasome inhibitors suppress production of TNF-a,
and NO, and exert their anti-inflammatory effects by
inhibiting NF-B, activation.
This conclusion was further supported by experimen-
tal testing of these inhibitors (dexamethasone, mevino-
lin, δ-tocotrienol, riboflavin and quercetin) in LPS-
stimulated thioglycolate-elicited peritoneal macrophages
derived from four different strains of mice. All inhibitors
significantly inhibited LPS-induced secretion of TNF-a
by macrophages derived from C57BL/6 and BALB/c
mice (Figure 9A). Although, macrophages derived from
C 5 7 B L / 6m i c ec o m p a r e dt oB A L B / cm i c ey i e l d e d
slightly better (20%) inhibition in LPS-stimulated secre-
tion of TNF-a (Figure 9A). In marked contrast to the
results attained with C57BL/6 and BALB/c mice, TNF-
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Page 18 of 25Figure 11 The effect of proteasome inhibitors on gene expression of TNF-a, and iNOS in LPS-induced peritoneal macrophages from
C57BL/6 mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-week-old C57BL/6 mice, adhered to the bottom of 12 well
plates (1 × 10
7 cells/well in 1 mL media) for 2 h, after 2 h, treated with 100 μL dissolved in 0.2% DMSO of a,-tocopherol (100 μM), δ-tocotrienol
(10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 2 h. Then cells were challenged with LPS (10 ng/well; 400 μL), and incubated at room
temperature for 4 h. Total cellular RNA was extracted and real-time polymerase chain reaction (RT-PCR) was conducted to quantitate expression
of TNF-a, (A), and iNOS (B) genes. Data are presented as the percent of mRNA for each of the genes analyzed compared to controls. The
treatments 1-5 correspond to: 1. Control (media + macrophages (cells) + LPS + 0.2% DMSO); 2. a,-tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5.
quercetin-HCL.
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Page 19 of 25Figure 12 The effect of proteasome inhibitors on gene expression of TNF-a, and iNOS in LPS-stimulated peritoneal macrophages from
BALB/c mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-week-old BALB/c mice, and adhered to the bottom of 12
wells plate (1 × 10
7 cells/well in 1 mL media) for 2 h, then treated with 100 μL dissolved in 0.2% DMSO of a,-tocopherol (100 μM), δ-tocotrienol
(10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 2 h. After 2 h, cells were challenged with LPS (10 ng/well; 400 μL), and incubated at
room temperature for 4 h. Total cellular RNA was extracted and real-time polymerase chain reaction (RT-PCR) was conducted to quantitate
expression of TNF-a, (A), and iNOS (B) genes. Cell viability exceeded > 95%) in all the treatments. Data are presented as the percent of mRNA for
each of the genes analyzed compared to controls. The treatments 1-5 correspond to: 1. Control (media + cells + LPS + 0.2% DMSO); 2. a,-
tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5. quercetin-HCL.
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Page 20 of 25Figure 13 The effect of proteasome inhibitors on gene expression of TNF-a, and iNOS in LPS-stimulated peritoneal macrophages from
LMP7/MECL-1
-/- knockout mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-week-old LMP7/MECL-1
-/- knockout mice,
adhered to the bottom of 12 wells plate (1 × 10
7 cells/well in 1 mL media) for 2 h, then treated with 100 μL dissolved in 0.2% DMSO of a,-
tocopherol (100 μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 2 h. After 2 h, the cells were challenged with LPS +
IFN-g (10 ng/well; 400 μL + 50 units/mL), and incubated at room temperature for 4 h. Total cellular RNA was extracted and real-time polymerase
chain reaction (RT-PCR) was conducted to quantitate expression of TNF-a, (A), and iNOS (B) genes. Cell viability exceeded > 95%) in all the
treatments. Data are presented as the percent of mRNA for each of the genes analyzed compared to controls. The treatments 1-5 correspond to:
The treatments 1-5 correspond to: 1. Control (media + cells + LPS + 0.2% DMSO); 2. a,-tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5. quercetin-HCL.
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Page 21 of 25Figure 14 The effect of proteasome inhibitors on gene expression of TNF-a, and iNOS in LPS-stimulated peritoneal macrophages from
PPAR-a,
-/- knockout mice. Thioglycollate-elicited peritoneal macrophages were prepared from 8-week-old PPAR-a,
-/- knockout mice, adhered to
the bottom of 12 wells plate (1 × 10
7 cells/well in 1 mL media) for 2 h, and treated with 100 μL dissolved in 0.2% DMSO of a,-tocopherol (100
μM), δ-tocotrienol (10 μM), riboflavin (40 μM), or quercetin-HCL (40 μM) for 2 h. Then cells were challenged with LPS (10 ng/well; 400 μL), and
incubated at room temperature for 4 h. Total cellular RNA was extracted and real-time polymerase chain reaction (RT-PCR) was conducted to
quantitate expression of TNF-a, (A), and iNOS (B) genes. Cell viability exceeded > 95%) in all the treatments. Data are presented as the percent
of mRNA for each of the genes analyzed compared to controls. The treatments 1-5 correspond to: The treatments 1-5 correspond to: 1. Control
(media + cells + LPS + 0.2% DMSO); 2. a,-tocopherol; 3. δ-tocotrienol; 4. riboflavin; 5. quercetin-HCL.
Qureshi et al. Lipids in Health and Disease 2011, 10:177
http://www.lipidworld.com/content/10/1/177
Page 22 of 25a, secretion was essentially unaffected by treatment of
LPS-stimulated macrophages derived from LMP7/
MECL-1
-/- knockout mice with δ-tocotrienol, riboflavin,
and quercetin (9B). Similarly, these compounds failed to
suppress TNF-a, secretion by LPS-stimulated macro-
phages derived from PPAR-a,
-/- knockout mice (since
activation of PPAR-a
-/- mice normally reduced inflam-
mation); δ-tocotrienol and riboflavin treatment actually
enhanced TNF-a, secretion (Figure 9B). In marked con-
trast to the observations with TNF-a, δ-tocotrienol,
riboflavin, and quercetin suppressed NO production by
LPS-stimulated macrophages from C57BL/6, BALB/c,
LMP7/MECL-1
-/-, and PPAR-a,
-/- knockout mice (Fig-
ure 10A, B). The effects of these proteasome inhibitors
on mRNA production by LPS-stimulated macrophages
were generally consistent with at the protein levels of
TNF-a, secretion and NO production.
Our previously published studies strongly support
the concept that proteasomes are key regulators of
LPS-stimulated inflammatory signaling pathways
(3,4,6-8). Proteolytic activity of proteasomes is
mediated by the 20S proteasomes, a hollow, cylindrical
multi-protein complex consisting of three proteolytic
subunits, X, Y, and Z, with chymotrypsin-like, trypsin-
like, and post-glutamase activities, respectively. A vari-
ety of inflammatory stimuli induce alterations in newly
assembled “immuno-proteasomes” in which X, Y and
Z subunits are partially replaced by LMP7, LMP2, and
MECL-1, respectively.
We previously demonstrated that low doses of lacta-
cystin, which suppresses primarily chymotrypsin-like
activity of the proteasome, potently suppressed produc-
tion of NO, but not TNF-a, by LPS stimulated macro-
phages. We further demonstrated that in order to
suppress TNF-a, secretion by LPS-stimulated macro-
phages with proteasome inhibitors, both chymotrypsin-
like and trypsin-like proteasome activities must be sup-
pressed (22). Subsequent experiments with proteasome
subunit knockout (LMP7
-/-,L M P 2
-/-,M E C L - 1
-/-,a n d
LMP7/MECL-1
-/-) revealed that NO production by LPS-
stimulated peritoneal macrophages was markedly
reduced in LMP7
-/-,L M P 2
-/-, MECL-1
-/-, and LMP7/
MECL-1
-/-knockout mice; TNF-a, production, in con-
trast, was not markedly affected by any of these knock-
out genotypes [23].
In the current study, the capacity of the investigated
proteasome inhibitors to inhibit TNF-a,s e c r e t i o nb y
LPS-stimulated macrophages from several sources (i.e.
the RAW 264.7 cell line, and peritoneal macrophages
from C57BL/6 and BALB/c mice) supports the conclu-
sion that these inhibitors suppress both chymotrypsin-
like and trypsin-like activities of the proteasomes, since
both of these activities must be suppressed in order to
inhibit TNF-a, secretion. These conclusions were
supported by our analysis of the effects of these inhibi-
tors on proteolytic activity of the proteasome.
The capacity of δ-tocotrienol, riboflavin, and quercetin
to block TNF-a, secretion in C57BL/6 and BALB/c, but
not in LMP7/MECL-1
-/- mice, is an intriguing result.
LPS-stimulation of macrophages from C57BL/6 and
BALB/c mice would be expected to induce production
of immunoproteasomes in which X, Y and Z subunits
were partially replaced by LMP2, LMP7 and MECL-1
-/-.
The × and Z components of LPS-stimulated macro-
phages from LMP7/MECL-1
-/- mice, however, cannot be
replaced by LMP7 and MECL-1
-/-. The macrophages
from knockout mice when induced produce robust
amounts of TNF-a,. Thus, the differential capacity of δ-
tocotrienol, riboflavin, and quercetin to inhibit TNF-a,
secretion by LPS-stimulated macrophages from C57BL/6
and BALB/c vs LMP7/MECL-1
-/- knockout mice would
appear to be attributable to a differential susceptibility
of × and Z vs LMP7 and MECL-1 proteasomal subunits
to inhibition by these inhibitors.
Presumably δ-tocotrienol, riboflavin, and quercetin are
potent inhibitors of LMP2, LMP7 and MECL-1
-/- subu-
nits of mouse immunoproteasomes, with comparatively
lesser suppressive effects on X, Y, and Z subunits of
constitutively expressed proteasomes. Thus, the chymo-
trypsin-like and trypsin-like activities of normal immu-
noproteasomes (containing LMP2, LMP7 and MECL-1
-/-
)f r o mC 5 7 B L / 6a n dB A L B / cm i c ew o u l db es u p p r e s s e d
by δ-tocotrienol, and quercetin, resulting in decreased
TNF-a, secretion. In contrast, the chymotrypsin-like
and trypsin-like activity of proteasomes (containing X,
Y, Z, and LMP2) from LMP7/MECL-1
-/- knockout mice
would not be suppressed by δ-tocotrienol, riboflavin,
and quercetin, resulting in normal TNF-a, secretion.
The finding that δ-tocotrienol, riboflavin, and querce-
tin inhibited NO production by LPS-stimulated macro-
phages from C57BL/6, BALB/c, LMP7/MECL-1
-/-,a n d
PPAR-a,
-/- mice was also quite interesting; the LMP7/
MECL-1
-/- genotype mice did not affect susceptibility to
inhibition by these compounds. These macrophages
from knockout mice do not induce very much NO,
therefore IFN-g had to be added along with LPS to
induce NO in cells that have X, Y, Z, and LMP2 subu-
nits [22].
PPAR-a,
-/- knockout mice have exaggerated inflamma-
tory responses to a variety of stimuli, because activation
of PPAR-a, leads to anti-inflammatory effects [24]. The
mechanisms leading to these exaggerated inflammatory
responses are not clearly understood, but are believed to
be at least partially attributable to increased NFB activ-
ity [24,25]. Consequently, one would expect TNF-a,
secretion by LPS-stimulated macrophages from PPAR-
a,
-/- knockout mice to be highly up-regulated with
respect to TNF-a, secretion and relatively resistant to
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Page 23 of 25inhibition by proteasome inhibitors that degrade IB,
and decrease NFB activity. Therefore, we found that δ-
tocotrienol, riboflavin, and quercetin failed to suppress
TNF-a, secretion by LPS-stimulated macrophages from
PPAR-a,
-/- knockout mice. In fact TNF-a, secretion was
substantially enhanced by riboflavin and δ-tocotrienol. A
clearer explanation of these results will be dependent on
further elucidation of interactions between PPAR-a, and
ubiquitin proteasome pathways [26].
Our present results demonstrate that δ-tocotrienol,
riboflavin, and quercetin are naturally-occurring potent
proteasome inhibitors for the inhibition of NO produc-
tion tested in vitro. These results also confirms earlier
report that g-tocotrienol blocked LPS-stimulated activa-
tion of NF-B, and also blocked TNF-a, induced phos-
phorylation and degradation of IBa,t h r o u g ht h e
inhibition of IBa, kinase activation [27]. Tocotrienols
have been shown to modestly inhibit or activate the pro-
teasomal activity depending on its concentrations
(Tables 1, [9]). Therefore, blocking the proteasomal
activity with low doses of tocotrienols could potentially
reduce inflammatory responses, but at high doses of
tocotrienols may cause apoptotic cell death in cancer
[9,28]. Quercetin, on the other hand is a natural protea-
some inhibitor that can affect several proteasomal
activities.
Conclusions
The present study describes the possible mechanism of
inhibition of NO production (released during ageing
processes or acute and chronic disease) by naturally-
occurring proteasome inhibitors (quercetin, δ-tocotrie-
nol, and riboflavin). Dexamethasone, mevinolin, δ-toco-
trienol, riboflavin and quercetin were all found to be
potent inhibitors of chymotrypsin-like activity of 20S
rabbit muscle proteasomes. δ-Tocotrienol, riboflavin,
and quercetin also inhibited chymotrypsin-like, trypsin-
like and post-glutamase activities of the proteasomes in
RAW 264.7 cells. These compounds also blocked LPS-
stimulated secretion of TNF-a, NO production, activa-
tion of NF-B, and degradation of P-IB in RAW 264.7
murine macrophages. Similarly, these compounds sup-
pressed TNF-a, secretion and NO production by LPS-
stimulated peritoneal macrophages derived from C57BL/
6 and BALB/c mice. δ-Tocotrienol, riboflavin, and quer-
cetin blocked the LPS-stimulated production of NO and
had no effect on the secretion of TNF-a, in macro-
phages derived from LMP7/MECL-1
-/- and PPAR-a,
-/-
knockout mice. These results indicate that δ-tocotrienol,
riboflavin, and quercetin treatments differentially inhibit
the secretion of TNF-a, of LPS-stimulated macrophages
derived from C57BL/6, BALB/c versus LMP7/MECL-1
-/-
and PPAR-a,
-/- knockout mice. Moreover, all the gene
expression results of TNF-a, and iNOS genes are
generally consistent with the results of protein levels of
secretion of TNF-a, and production of NO observed
with either C57BL/6, BALB/c, LMP7/MECL-1
-/-,o r
PPAR-a,
-/- mice. All these results indicate that the pro-
duction of NO may be modulated via NF-Bp a t h w a y ,
and δ-tocotrienol acts as a proteasome inhibitor at
lower doses and as activator at higher doses (Table 1).
These collective properties of δ-tocotrienol, riboflavin,
and quercetin can be referred to as “novel proteasome
inhibitors”, which might be used to suppress the pro-
duction of inflammatory mediators in ageing humans,
thereby decreasing the risk of developing a variety of
age-related diseases that appear to be at least partially
attributable to aberrant control of inflammatory
responses with increasing age.
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